

## Reference Data

1st Quarter - Fiscal Year 2019  
(April 1, 2019 to June 30, 2019)

### Consolidated Earnings

- Consolidated Financial Data P 1
- Consolidated Balance Sheets P 2
- Consolidated P/L Statement P 3
- Consolidated Sales Breakdown by Segment/Category P 4
- Consolidated Operating Income by Segment P 4
- Consolidated Sales -
  - Leading Brands of Self-Medication Operations
  - Sales by Region P 5
- Consolidated Sales -
  - Leading Products of Prescription Pharmaceutical Operations P 6
- Capital Expenditure P 7
- Depreciation and Amortization P 7
- R&D Expenses P 7
- Results of Major Consolidated Subsidiaries
  - ◆ Taisho Pharmaceutical P 8
- Major Subsidiaries and Affiliates P 9
- Prescription Pharmaceutical Operations:
  - New Drug Development-Taisho Pharmaceutical P10
- Launch of New Products P12

## Consolidated Financial Data

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9 new)	2Q E (4-9 previous)	Full year E (new)	Full year E (previous)
Net sales	61,748	129,491	199,896	261,551	60,260	131,000	126,500	293,500	253,500
(YOY%)	(-9.9%)	(-6.6%)	(-7.4%)	(-6.6%)	(-2.4%)	(+1.2%)	(-2.3%)	(+12.2%)	(-3.1%)
Self-Medication operations	42,491	89,785	137,815	180,123	42,936	96,500	92,000	225,500	185,500
Prescription Pharmaceutical operations	19,257	39,705	62,080	81,428	17,323	34,500	34,500	68,000	68,000
Gross profit on sales*	40,547	85,301	130,820	170,163	41,305	88,200	86,100	190,000	172,000
Selling, general and administrative expenses	32,389	68,310	102,703	138,951	32,981	74,200	69,600	157,000	136,500
Research and development expenses	4,376	9,479	14,175	20,801	4,991	11,500	11,500	22,600	22,600
(% Sales)	(7.1%)	(7.3%)	(7.1%)	(8.0%)	(8.3%)	(8.8%)	(9.1%)	(7.7%)	(8.9%)
Advertising expenses	4,277	9,533	15,332	20,206	4,800	11,800	11,700	24,100	23,100
Sales promotion expenses	6,218	12,853	20,048	27,125	5,474	14,800	14,500	29,800	27,900
Personnel expenses	8,598	17,060	25,182	32,491	6,838	14,700	13,900	32,400	27,500
Operating Profit	8,157	16,991	28,116	31,211	8,324	14,000	16,500	33,000	35,500
(YOY%)	(+17.5%)	(+11.9%)	(-1.5%)	(-15.6%)	(+2.0%)	(-17.6%)	(-2.9%)	(+5.7%)	(+13.7%)
Ordinary Profit	12,205	22,710	36,163	40,851	7,649	14,500	20,000	37,000	42,500
(YOY%)	(+38.8%)	(+27.2%)	(+8.3%)	(-3.1%)	(-37.3%)	(-36.2%)	(-11.9%)	(-9.4%)	(+4.0%)
Profit attributable to owners of parent	13,689	42,434	51,398	48,593	11,006	15,500	13,500	29,500	28,500
(YOY%)	(+147.3%)	(+253.1%)	(+94.2%)	(+53.4%)	(-19.6%)	(-63.5%)	(-68.2%)	(-39.3%)	(-41.4%)
Comprehensive income	12,587	42,079	44,350	48,027	5,301	-	-	-	-
(YOY%)	(+22.2%)	(+105.7%)	(+21.1%)	(+31.1%)	(-57.9%)	-	-	-	-
Basic EPS (yen)	171.50	531.62	643.93	608.80	137.91	194.21	169.15	369.64	357.11
Diluted EPS (yen)	171.35	531.14	643.33	608.22	137.77	194.01	168.98	369.24	356.73
BPS (yen)	8,542.77	8,906.59	8,881.55	8,924.23	8,917.17	9,140.01	9,027.24	9,537.06	9,161.15
Dividend per share (yen)	-	50.00	-	120.00	-	50.00	50.00	110.00	110.00
Payout ratio	-	-	-	19.7%	-	-	-	29.8%	30.8%
Capital expenditure	733	1,670	2,961	5,259	987	2,360	2,360	5,530	5,530
Depreciation and amortization	2,438	4,918	7,481	10,073	2,391	4,410	4,410	9,260	9,260
Total assets	795,842	841,336	830,520	821,782	824,112	844,000	829,000	892,000	841,000
Shareholders' equity	694,483	722,348	720,458	724,137	730,661	741,000	732,000	773,000	743,000
Return on equity (%)**	-	-	-	7.0%	-	-	-	4.0%	3.9%
Return on assets (%)**	-	-	-	6.0%	-	-	-	3.4%	3.4%
Equity ratio (%)**	85.7%	84.5%	85.4%	86.7%	86.4%	86.4%	86.9%	85.3%	86.9%
Overseas sales	7,849	15,673	23,411	30,978	7,874	20,800	16,300	72,500	32,500
Overseas sales ratio (% of total sales)	12.7%	12.1%	11.7%	11.8%	13.1%	15.9%	12.9%	24.7%	12.8%
Number of employees	6,305	6,215	5,728	5,142	8,105	-	-	-	-

\* After provision/reversal of reserve for returned unsold goods

\*\* Average of the beginning and year-end balance of shareholders' equity / total assets

<Reference>

-E= Estimates

• The 2Q and full year forecasts (previous) for the fiscal year ending March 31, 2020 were announced on May 13, 2019.

# Consolidated Balance Sheets

(Millions of yen)

	End of FY2018		End of FY2019/1Q		change	
	(March 31, 19)	% total	(Jun. 30, 19)	% total		
<b>(Assets)</b>						
I Current assets:	469,781	57.2%	478,880	58.1%	+9,099	
Cash and deposits	282,567		290,299		+7,732	
Notes and accounts receivable-trade	71,286		69,030		-2,256	
Marketable securities	75,900		75,233		-666	
Inventories	29,517		35,038		+5,521	
Other	10,509		9,278		-1,230	
II Fixed assets:	352,001	42.8%	345,231	41.9%	-6,769	
(1) Tangible fixed assets:	91,283	(11.1%)	94,315	(11.4%)	+3,032	
Buildings and structures	45,764		46,731		+966	
Machinery, equipment and vehicles	5,217		6,801		+1,583	
Land	37,008		37,457		+448	
Other	3,292		3,325		+33	
(2) Intangible fixed assets:	24,302	(3.0%)	54,698	(6.6%)	+30,396	
Goodwill	12,534		42,963		+30,429	Effect of the consolidation of Hau Giang Pharmaceutical that is being implemented
Sales rights	1,419		1,088		-330	
Trademarks	5,657		5,401		-255	
Software	4,086		4,394		+307	
Other	604		849		+244	
(3) Investments and other assets:	236,416	(28.8%)	196,218	(23.8%)	-40,197	
Investment securities	172,432		165,134		-7,297	
Shares of subsidiaries and affiliates	31,262		11,810		-19,451	
Net defined benefit assets	5,765		5,869		+104	
Deferred tax assets	9,365		11,335		+1,969	
Other	17,590		2,067		-15,522	
<b>Total assets</b>	<b>821,782</b>	<b>100.0%</b>	<b>824,112</b>	<b>100.0%</b>	<b>+2,329</b>	
<b>(Liabilities)</b>						
I Current liabilities:	58,453	7.1%	55,619	6.7%	-2,833	
Notes and accounts payable-trade	18,814		16,212		-2,602	
Accounts payable	14,276		13,289		-987	
Accrued income taxes	8,607		4,270		-4,336	
Provision for bonuses	3,123		1,693		-1,430	
Other	13,630		20,154		+6,523	
II Long-term liabilities:	39,192	4.8%	37,831	4.6%	-1,360	
Net defined benefit liabilities	18,715		19,578		+863	
Deferred taxes liabilities	13,530		11,740		-1,789	
Other	6,946		6,512		-434	
<b>Total liabilities</b>	<b>97,645</b>	<b>11.9%</b>	<b>93,451</b>	<b>11.3%</b>	<b>-4,194</b>	
<b>(Net assets)</b>						
I Shareholders' equity	683,025	83.1%	688,432	83.5%	+5,406	
Common stock	30,000	3.7%	30,000	3.6%	-	
Capital surplus	14,924	1.8%	-	-	-14,924	Impact of the cancellation of treasury stock
Retained earnings	706,742	86.0%	693,883	84.2%	-12,859	Profit attributable to owners of parent+11,006, Impact of the cancellation of treasury stock
Treasury stock	-68,641	-8.4%	-35,450	-4.3%	+33,190	Impact of the cancellation of treasury stock
II Accumulated other comprehensive income	29,258	3.6%	23,280	2.8%	-5,978	
Valuation difference on securities	32,017	3.9%	26,292	3.2%	-5,724	
Deferred gains or losses on hedges	2,181	0.3%	1,107	0.1%	-1,073	
Foreign currency translation adjustment	-2,130	-0.3%	-1,335	-0.2%	+794	
Remeasurements of defined benefit plans	-2,809	-0.3%	-2,783	-0.3%	+25	
III Share acquisition rights	687	0.1%	687	0.1%	-	
IV Non-controlling interests	11,165	1.4%	18,261	2.2%	+7,095	
<b>Total net assets</b>	<b>724,137</b>	<b>88.1%</b>	<b>730,661</b>	<b>88.7%</b>	<b>+6,524</b>	
<b>Total liabilities and net assets</b>	<b>821,782</b>	<b>100.0%</b>	<b>824,112</b>	<b>100.0%</b>	<b>+2,329</b>	

## Consolidated P/L Statement

(Millions of yen)

	FY2018		FY2019		YOY change	
	1Q	% total	1Q	% total		
Net sales	61,748	100.0%	60,260	100.0%	-1,488	
Cost of sales	21,295	34.5%	19,037	31.6%	-2,258	
Gross profit on sales	40,453	65.5%	41,223	68.4%	+769	
Provision for sales returns	-93		-82		+11	
Gross profit	40,547	65.7%	41,305	68.5%	+758	
Selling, general and administrative expenses	32,389	52.5%	32,981	54.7%	+591	
Research and development expenses	4,376		4,991		+614	
Advertising expenses	4,277		4,800		+522	
Sales promotion expenses	6,218		5,474		-744	
Personnel expenses	8,598		6,838		-1,760	
Other	8,918		10,877		+1,959	
Operating Profit	8,157	13.2%	8,324	13.8%	+166	
Non-operating income	4,072	6.6%	2,306	3.8%	-1,766	Equity in gains of affiliates -1,258
Non-operating expenses	24	0.0%	2,981	4.9%	+2,956	Foreign exchange losses 2,932
Ordinary Profit	12,205	19.8%	7,649	12.7%	-4,555	
Extraordinary income	0	0.0%	6,093	10.1%	+6,093	Gains attributable to phased acquisition 6,093
Extraordinary losses	1	0.0%	3	0.0%	+1	
Profit before income taxes and minority interests	12,203	19.8%	13,740	22.8%	+1,536	
Income taxes	-1,889	-3.1%	2,414	4.0%	+4,304	FY2018: Decrease in income taxes – deferred due to a resolution on the sale of shares in Toyama Chemical Co., Ltd
Profit	14,093	22.8%	11,325	18.8%	-2,767	
Profit attributable to non-controlling interests	403	0.7%	318	0.5%	-85	
Profit attributable to owners of parent	13,689	22.2%	11,006	18.3%	-2,682	

## Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9 new)	2Q E (4-9 previous)	Full year E new	Full year E previous
Self-Medication operations	42,491	89,785	137,815	180,123	42,936	96,500	92,000	225,500	185,500
(YOY%)	(-5.2%)	(-2.3%)	(-2.2%)	(-2.1%)	(+1.0%)	(+7.5%)	(+2.5%)	(+25.2%)	(+3.0%)
Japan	34,016	72,608	112,126	145,983	34,428	74,500	74,500	150,500	150,500
Overseas	7,747	15,567	23,303	30,867	7,821	20,700	16,200	72,300	32,300
Other	726	1,609	2,385	3,272	687	1,300	1,300	2,700	2,700
Prescription Pharmaceutical operations	19,257	39,705	62,080	81,428	17,323	34,500	34,500	68,000	68,000
(YOY%)	(-18.8%)	(-15.1%)	(-17.2%)	(-15.3%)	(-10.0%)	(-13.1%)	(-13.1%)	(-16.5%)	(-16.5%)
Ethical drugs	18,253	38,320	60,326	79,460	16,682	33,300	33,300	66,500	66,500
Other	1,003	1,384	1,754	1,967	640	1,200	1,200	1,500	1,500
Total	61,748	129,491	199,896	261,551	60,260	131,000	126,500	293,500	253,500

## Consolidated Operating Profit by Segment

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9 new)	2Q E (4-9 previous)	Full year E new	Full year E previous
Self-Medication operations	7,574	16,858	26,242	30,287	7,032	12,800	15,300	31,000	33,500
(YOY%)	(+29.6%)	(+17.8%)	(+18.1%)	(+0.4%)	(-7.2%)	(-24.1%)	(-9.2%)	(+2.4%)	(+10.6%)
Prescription Pharmaceutical operations	906	1,228	3,312	2,685	1,605	1,900	1,900	3,500	3,500
(YOY%)	(-35.9%)	(-21.5%)	(-55.2%)	(-67.3%)	(+77.2%)	(-)	(+54.7%)	(+30.3%)	(+30.3%)
Other*	-323	-1,095	-1,437	-1,760	-313	-700	-700	-1,500	-1,500
(YOY%)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Total	8,157	16,991	28,116	31,211	8,324	14,000	16,500	33,000	35,500

\* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2019(FY2018)				March 2020(FY2019)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9 new)	2Q E (4-9 previous)	Full year E (new)	YOY	Full year E (previous)
Japan	34.0	72.6	112.1	146.0	34.4	+1.2%	74.5	74.5	150.5	+3.1%	150.5
Lipovitan series	13.3	29.2	41.8	52.0	12.8	-4.0%	29.2	29.2	52.7	+1.3%	52.7
Pabron series	5.1	11.4	20.8	28.9	5.8	+12.8%	11.7	11.7	29.1	+0.7%	29.1
RiUP series	3.4	7.6	11.8	15.3	3.6	+5.9%	7.7	7.7	15.3	+0.0%	15.3
Biofermin series	2.4	5.1	7.8	10.2	2.5	+6.2%	5.3	5.3	10.6	+3.9%	10.6
VICKS series	0.6	1.5	3.1	4.0	0.7	+8.0%	1.6	1.6	4.1	+2.9%	4.1
GI treatment series	0.8	1.7	2.8	3.7	0.9	+3.9%	1.6	1.6	3.6	-3.3%	3.6
Livita series	0.8	1.5	2.7	3.4	0.8	-0.2%	1.7	1.7	3.6	+5.0%	3.6
Colac series	0.7	1.4	2.3	3.0	0.8	+10.6%	1.5	1.5	3.0	-0.5%	3.0
NARON series	0.7	1.5	2.3	3.0	0.7	+3.0%	1.5	1.5	3.1	+4.1%	3.1
Overseas	7.7	15.6	23.3	30.9	7.8	+1.0%	20.7	16.2	72.3	+134.2%	32.3
Asia	6.8	13.9	20.7	27.6	7.2	+5.1%	19.0	14.5	42.9	+55.3%	28.9
Europe and America	0.3	0.8	1.4	1.9	0.5	+45.9%	1.1	1.1	28.2	-	2.2
Others	0.7	1.6	2.4	3.3	0.7	-5.4%	1.3	1.3	2.7	-17.5%	2.7

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2019(FY2018)				March 2020(FY2019)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Lipovitan series	13.3	29.2	41.8	52.0	12.8	-4.0%	29.2	52.7	+1.3%
Lipovitan D	8.6	18.9	27.0	33.4	8.3	-3.7%	18.4	32.7	-2.0%
Others	4.7	10.2	14.8	18.7	4.5	-4.7%	10.8	20.1	+7.4%
(100mL other Lipovitans)	3.2	6.7	9.8	12.3	3.0	-4.4%	7.0	13.1	+6.4%
(50mL other Lipovitans)	1.5	3.5	5.0	6.4	1.5	-5.4%	3.8	7.0	+9.4%

(Rounded to the nearest hundred-million)

## Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2019(FY2018)				March 2020(FY2019)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Edirol	5.9	12.6	19.8	26.2	6.5	+10.1%	14.0	27.7	+5.7%
Bonviva	1.4	3.0	4.8	6.4	1.6	+10.4%	3.3	6.8	+6.5%
Lusefi	1.1	2.7	4.0	5.6	1.9	+65.8%	3.3	6.7	+19.3%
Clarith	1.2	2.3	4.0	5.3	1.1	-4.5%	1.9	4.0	-24.9%
LOQOA	0.8	1.6	2.6	3.5	0.9	+16.4%	1.9	3.9	+12.1%
Biofermin	1.1	2.0	2.9	3.9	1.0	-7.5%	1.9	3.9	-1.1%
Geninax	0.2	1.4	2.6	3.5	0.8	+250.5%	1.5	3.3	-5.9%
Palux	0.9	1.8	2.7	3.5	0.8	-3.9%	1.6	3.1	-12.6%

(Rounded to the nearest hundred-million)

## Consolidated: Capital Expenditure

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total capital expenditure	733	1,670	2,961	5,259	987	2,360	5,530
Taisho Pharmaceutical	492	1,117	2,050	3,974	748	1,960	4,520
Production department	101	406	671	1,061	67	750	1,870
Research department	114	357	644	979	38	170	530
Head Office and the others	275	353	734	1,932	642	1,040	2,120
Other subsidiaries	241	553	910	1,285	238	400	1,010

\*The forecasts do not reflect the impact of the conversion of Hau Giang Pharmaceutical and UPSA into subsidiaries.

## Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Depreciation and amortization	2,438	4,918	7,481	10,073	2,391	4,410	9,260
Cost of sales	751	1,518	2,308	3,225	749	1,610	3,570
SGA expenses	1,687	3,400	5,172	6,847	1,641	2,800	5,690

\*The forecasts do not reflect the impact of the conversion of Hau Giang Pharmaceutical and UPSA into subsidiaries.

## Consolidated: R&D Expenses

(Millions of yen)

	March 2019(FY2018)				March 2020(FY2019)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total R&D expenses	4,376	9,479	14,175	20,801	4,991	11,500	22,600
Self-Medication operations	1,263	2,585	3,796	5,353	1,398	3,400	6,400
Prescription Pharmaceutical operations	3,113	6,893	10,379	15,447	3,592	8,100	16,200

## Result of Major Consolidated Subsidiary

### Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2019(FY2018)				March 2020(FY2019)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9 new)	2Q E (4-9 previous)	Full year E (new)	YOY	Full year E (previous)
Net Sales	45.4	95.1	147.7	192.9	51.8	+14.2%	109.0	109.0	219.0	+13.5%	219.0
Self-Medication	34.6	73.6	113.6	147.7	34.6	-0.0%	75.0	75.0	151.0	+2.2%	151.0
Prescription Pharmaceutical	10.7	21.5	34.1	45.2	17.2	+60.2%	34.0	34.0	68.0	+50.6%	68.0
Operating profit	5.4	11.0	18.9	20.3	6.6	+21.9%	10.0	13.0	26.0	+27.9%	29.0
Ordinary profit	8.3	15.9	24.1	27.9	3.9	-52.9%	11.0	17.0	30.0	+7.7%	36.0
Profit	6.5	5.7	11.2	11.5	2.9	-54.6%	9.0	13.0	24.0	+108.2%	28.0

(Rounded to the nearest hundred-million)

## Major Subsidiaries and Affiliates

(As of June 30, 2019)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 165,300	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

\*Ownership: including the portion of indirect ownership

The above list does not include UPSA, shares of which were acquired on July 1, 2019.

# Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of July 29, 2019

In Japan

Phase 3

## **TS-152 (Injection)**

- < Application > Rheumatoid arthritis
- < Development > In-license (Licensor: Ablynx)
- < Description > Anti-TNF(Tumor Necrosis Factor)- $\alpha$  antibody
- < Remarks > Generic name: Ozoralizumab

Phase 2

## **TS-091 (Oral)**

- < Application > Central disorders of hypersomnolence
- < Development > In-house

## **TS-141 (Oral)**

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < Development > In-house

## **TS-133 (Topical)**

- < Application > Alopecia
- < Development > In-house

## **TS-142 (Oral)**

- < Application > Insomnia
- < Development > In-house

# Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of July 29, 2019

## Overseas

Phase 2
---------

### **TS-121 (Oral)**

< Application > Depression  
< Development > In-house

Phase 1
---------

### **TS-091 (Oral)**

< Target disease > Central disorders of hypersomnolence  
< In-house/Licensed-in > In-house

### **TS-134 (Oral)**

< Target disease > Schizophrenia  
< In-house/Licensed-in > In-house

### **TS-161 (Oral)**

< Target disease > Depression  
< In-house/Licensed-in > In-house

## Launch of New Products

As of July 29, 2019

### New Products Since FY2018 Earnings Announcement (May 13, 2019)

Self-Medication Operations
----------------------------

#### **AdryS**

< Description > A new skin care brand for products that provide moisturizing and skin-brightening effects to dry skin. Products offer a comfortable texture and the combination of heparinoid and placenta extract, namely, pharmaceutical moisturizing and skin-brightening ingredients.

< Launch > May 2019

---

#### **Lipovitan Crear \*mail order**

< Description > A mini-energy drink ideal for people who are concerned about eye strain and body fatigue. The product contains taurine, royal jelly, kukoshi (a crude drug) and vitamin B<sub>1</sub>, which are effective for the alleviation of eye strain caused by undernourishment.

< Launch > June 2019

---

#### **Lipovitan D : Japanese professional baseball teams bottle**

< Description > The Lipovitan D Professional Baseball Team Bottles with the 11 baseball teams will launch in this season. Featuring four new bottle designs for each team, instead of the single bottle design for each team in the previous season.

< Launch > June 2019

---